Radium 223 in bone metastases from radioactive iodine refractory thyroid cancer: single arm Phase II trial preliminary results .
Thyroid World Congress ePoster Library. Deandreis D. 06/22/19; 272135; 145
Desiree Deandreis
Desiree Deandreis
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Rate & Comment (0)

Purpose: to evaluate the efficacy of Radium 223 in patients with bone metastases from radioactive iodine (RAI) refractory thyroid cancer (DTC). Methods: This is a multicenter single arm two-stage Simon Phase II trial (NCT02390934). Primary objective was to establish the efficacy of 3 monthly Radium-223 administrations (3M) by FDG PET/CT. Main secondary objectives were: to establish the efficacy of 6 monthly administrations of Radium-223 (6M) by FDG PET/CT, 3M and 6M response on bone scan and 18 NaF PET/CT and safety .Results: 10 patients were prospectively enrolled between July 2015 and December 2017 (4 M; 6F; Median Age 74 y, range 62-76). Patients presented with Papillary (n=5), Follicular (n=3), Poorly differentiated TC (n=2). Median number of RAI treatments received before Radium 223 was 4 (3-6). Patients received previously external radiation therapy (n=9), thermal ablation (n=3) and bone surgery (n=8). 9/10 patients received 6 cycles of radium 223, 1 patient stopped after 3 cycles because of bone skeletal event. 3M response at FDG PET was Stable Disease (SD) in 6/10 and progressive disease (PD) in 4/10 cases. In 9 evaluable patients 6M response at FDG PET was SD in 5 cases and PD in 4 cases.6M response at bone scan was SD in 9/9 cases and at 18NaF PET/CT was SD in 8 cases and Partial Response (PR) in 1 case. 2 patients developed acute myeloid and promyelocitic leukemia  during follow up. Conclusions: Trial was stopped for absence of response to Radium 223 at FDG PET and severe hematological events.


Purpose: to evaluate the efficacy of Radium 223 in patients with bone metastases from radioactive iodine (RAI) refractory thyroid cancer (DTC). Methods: This is a multicenter single arm two-stage Simon Phase II trial (NCT02390934). Primary objective was to establish the efficacy of 3 monthly Radium-223 administrations (3M) by FDG PET/CT. Main secondary objectives were: to establish the efficacy of 6 monthly administrations of Radium-223 (6M) by FDG PET/CT, 3M and 6M response on bone scan and 18 NaF PET/CT and safety .Results: 10 patients were prospectively enrolled between July 2015 and December 2017 (4 M; 6F; Median Age 74 y, range 62-76). Patients presented with Papillary (n=5), Follicular (n=3), Poorly differentiated TC (n=2). Median number of RAI treatments received before Radium 223 was 4 (3-6). Patients received previously external radiation therapy (n=9), thermal ablation (n=3) and bone surgery (n=8). 9/10 patients received 6 cycles of radium 223, 1 patient stopped after 3 cycles because of bone skeletal event. 3M response at FDG PET was Stable Disease (SD) in 6/10 and progressive disease (PD) in 4/10 cases. In 9 evaluable patients 6M response at FDG PET was SD in 5 cases and PD in 4 cases.6M response at bone scan was SD in 9/9 cases and at 18NaF PET/CT was SD in 8 cases and Partial Response (PR) in 1 case. 2 patients developed acute myeloid and promyelocitic leukemia  during follow up. Conclusions: Trial was stopped for absence of response to Radium 223 at FDG PET and severe hematological events.


    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.


Save Settings